FilmArray BCID Panel, RFIT-ASY-0126, 30, Rx Only, CE, IVD, UDI: 00815381020086 used with the following BACT/ALERT Blood Culture Bottle Catalog No./Description: 410851/BACT/ALERT® FA Plus 410852/BACT/ALERT® FN Plus 410853/BACT/ALERT® PF Plus 259790/BACT/ALERT® SN Product Usage: is a qualitative multiplexed nucleic acid-based in vitro diagnostic test intended for use with FilmArray systems.
Publicado el 17 de junio de 2020 · Inicio del retiro: 22 de enero de 2020
Resumen
FDA registra el retiro Z-2295-2020 de dispositivos médicos de Clase II, publicado el 17 de junio de 2020 e iniciado el 22 de enero de 2020. Empresa responsable: BioFire Diagnostics, LLC; Estado: Finalizado; Cantidad reportada: 18,501 kits; Lote: All lots of BioFire BCID Panel used with BACT/ALERT® blood culture bottles with expiration dates of September 19, 2020 and beyond. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
There is an increased risk of false positive Proteus results when using the Film Array Blood Culture Identification Panel (BCID) in vitro diagnostic test of blood cultures used in conjunction with specific media types. False positive Proteus results from this test may lead to patients receiving improper antibiotic treatment until culture results are available (within 24-48 hours).
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- BioFire Diagnostics, LLC
- Distribuidor
- Worldwide distribution - US Nationwide distribution and the countries of Argentina, Austria, Australia, Azerbaijan, Belgium, Bosnia-Herz., Botswana, Brazil, Bulgaria, Burkina Faso, Canada, Chile, Columbia, Costa Rica, Croatia, Czech Republic, Dominican Republic, Dutch Antilles, Ecuador, Egypt, El Salvador, Estonia, France, Gabon, Georgia, Germany, Greece, Guam, Guatemala, Honduras, Hong Kong, Hungary, India, Indonesia, Iraq, Israel, Italy, Ivory Coast, Japan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Mexico, Morocco, Myanmar, Netherlands, Nicaragua, Oman, Pakistan, Panama, Paraguay, Peru, Phillipines, Poland, Portugal, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, South Africa, South Korea, Spain, Sweden, Sitzerland, Thailand, Tunisia, Turkey, United Kingdom, Uruguay, United Arab Emirates, Vietnam.
- Lote
- All lots of BioFire BCID Panel used with BACT/ALERT® blood culture bottles with expiration dates of September 19, 2020 and beyond.
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAGeneric Name: FilmArray® Pneumonia Panel Generic Name: FilmArray® Pneumonia Panel Model/Catalog Number:21 de octubre de 2026
- FDAGeneric Name: FilmArray® Pneumonia Panel plus Generic Name: FilmArray® Pneumonia Panel plus Model/Catalog21 de octubre de 2026
- FDAGeneric Name: BioFire® Joint Infection (JI) Panel Generic Name: BioFire® Joint Infection (JI) Panel21 de octubre de 2026
- FDABIOFIRE Respiratory Panel 2.1 (RP2.1) REF 423742 UDI code: 00815381020529 PCR-based multiplexed nucleic acid19 de agosto de 2026
- FDAtherascreen EGFR RGQ PCR Kit (24), Reference Number REF 87012117 de junio de 2020
- FDAMulti Display Manager in the Artis Systems (Image-Intensified Fluoroscopic X-Ray System) as follows: Artis Q17 de junio de 2020
Preguntas sobre este retiro
¿FilmArray BCID Panel, RFIT-ASY-0126, 30, Rx Only, CE, IVD, UDI: 00815381020086 used with the following BACT/ALERT Blood Culture Bottle Catalog No./Description: 410851/BACT/ALERT® FA Plus 410852/BACT/ALERT® FN Plus 410853/BACT/ALERT® PF Plus 259790/BACT/ALERT® SN Product Usage: is a qualitative multiplexed nucleic acid-based in vitro diagnostic test intended for use with FilmArray systems. fue retirado del mercado?
Sí. FDA publicó el retiro Z-2295-2020 el 17 de junio de 2020. Peligro reportado: There is an increased risk of false positive Proteus results when using the Film Array Blood Culture Identification Panel (BCID) in vitro diagnostic test of blood cultures used in conjunction with specific media types. False positive Proteus results from this test may lead to patients receiving improper antibiotic treatment until culture results are available (within 24-48 hours).
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter